Acadia Lifts 2026 Outlook as DAYBUE STIX Demand Drives 16% Revenue Jump
ACAD sits 38% above its 52-week low of $19.69.
Summary
Acadia's Q2 revenue rose 16% year-over-year to $307.96 million, fueled by strong demand for DAYBUE STIX and NUPLAZID. Net income swung to $31.5 million from a prior-year loss, and the company raised its full-year 2026 revenue guidance to $1.24-$1.30 billion, with DAYBUE sales now seen at $480-$510 million. This follows the positive EU opinion for DAYBUE in June and the recent Fast Track designation for remlifanserin, reinforcing the commercial momentum. The raised outlook and upcoming Phase 2 Alzheimer's psychosis data in September-October provide clear catalysts for further upside.
At the time of this announcement, ACAD was trading at $27.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $19.69 to $28.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.